Leptomycin B
Names
[ CAS No. ]:
87081-35-4
[ Name ]:
Leptomycin B
[Synonym ]:
Leptomycin B,(2E,5S,6R,7S,9R,10E,12E,15R,16Z,18E)-19-[(2S,3S)-3,6-Dihydro-3-methyl-6-oxo-2H-pyran-2-yl]-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-2,10,12,16,18-nonadecapentaenoicacid
2,10,12,16,18-nonadecapentaenoic acid
2,10,12,16,18-Nonadecapentaenoic acid, 19-[(2S,3S)-3,6-dihydro-3-methyl-6-oxo-2H-pyran-2-yl]-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-, (2E,5S,6R,7S,9R,10E,12E,15R,16E,18E)-
2,10,12,16,18-Nonadecapentaenoic acid, 19-[(2S,3S)-3,6-dihydro-3-methyl-6-oxo-2H-pyran-2-yl]-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-, (2E,5S,6R,7S,9R,10E,12E,15R,16Z,18E)-
7,9,11,15-hexamethyl-8-oxo--yl)-17-ethyl-6-hydroxy-5
(2E,5S,6R,7S,9R,10E,12E,15R,16E,18E)-17-Ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-19-[(2S,3S)-3-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl]-8-oxo-2,10,12,16,18-nonadecapentaenoic acid
antibioticci940
(2E,5S,6R,7S,9R,10E,12E,15R,16Z,18E)-17-Ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-19-[(2S,3S)-3-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl]-8-oxo-2,10,12,16,18-nonadecapentaenoic acid
antibioticcl1957a
LEPTOMYCIN B FROM STREPTOMYCES SP
Leptomycin B
Biological Activity
[Description]:
[Related Catalog]:
[Target]
CRM1/exportin 1[1]
[References]
Chemical & Physical Properties
[ Density]:
1.1±0.1 g/cm3
[ Boiling Point ]:
725.8±60.0 °C at 760 mmHg
[ Melting Point ]:
41-44ºC
[ Molecular Formula ]:
C33H48O6
[ Molecular Weight ]:
540.73
[ Flash Point ]:
224.8±26.4 °C
[ Exact Mass ]:
540.345093
[ PSA ]:
100.90000
[ LogP ]:
6.66
[ Vapour Pressure ]:
0.0±5.3 mmHg at 25°C
[ Index of Refraction ]:
1.542
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- RA5390000
- CHEMICAL NAME :
- 2,10,12,16,18-Nonadecapentanoic acid, 19-(3,6-dihydro-3-methyl-6-oxo-2H-pyran-2-yl)-17-ethy l- 6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-
- CAS REGISTRY NUMBER :
- 87081-35-4
- LAST UPDATED :
- 199412
- DATA ITEMS CITED :
- 3
- MOLECULAR FORMULA :
- C33-H48-O6
- MOLECULAR WEIGHT :
- 540.81
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 3100 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
MUTATION DATA
- TYPE OF TEST :
- Mutation test systems - not otherwise specified
- TEST SYSTEM :
- Rodent - mouse Leukocyte
- DOSE/DURATION :
- 1 umol/L
- REFERENCE :
- PAACA3 Proceedings of the American Association for Cancer Research. (Waverly Press, 428 E. Preston St., Baltimore, MD 21202) V.1- 1954- Volume(issue)/page/year: 26,253,1985
Safety Information
[ Symbol ]:
GHS02, GHS06, GHS08
[ Signal Word ]:
Danger
[ Hazard Statements ]:
H225-H301-H311-H331-H370
[ Precautionary Statements ]:
P210-P260-P280-P301 + P310-P311
[ Hazard Codes ]:
T: Toxic;F: Flammable;
[ Risk Phrases ]:
R23/25
[ Safety Phrases ]:
7-16-24-33-45
[ RIDADR ]:
UN 1230 3
[ WGK Germany ]:
3
[ HS Code ]:
2916190090
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Customs
[ HS Code ]: 2916190090
[ Summary ]:
2916190090 unsaturated acyclic monocarboxylic acids, their anhydrides, halides, peroxides, peroxyacids and their derivatives。supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward)。VAT:17.0%。tax rebate rate:9.0%。MFN tariff:6.5%。general tariff:30.0%
Articles
J. Virol. 89(9) , 4918-31, (2015)
The ORF45 protein of Kaposi's sarcoma-associated herpesvirus (KSHV) is a gammaherpesvirus-specific immediate-early tegument protein. Our previous studies have revealed its crucial roles in both early ...
African swine fever virus ORF P1192R codes for a functional type II DNA topoisomerase.Virology 474 , 82-93, (2014)
Topoisomerases modulate the topological state of DNA during processes, such as replication and transcription, that cause overwinding and/or underwinding of the DNA. African swine fever virus (ASFV) is...
Identification of novel DNA-damage tolerance genes reveals regulation of translesion DNA synthesis by nucleophosmin.Nat. Commun. 5 , 5437, (2014)
Cells cope with replication-blocking lesions via translesion DNA synthesis (TLS). TLS is carried out by low-fidelity DNA polymerases that replicate across lesions, thereby preventing genome instabilit...